An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from Â鶹´«Ã½
Explore the latest news, articles and features
Popular articles
Trending Â鶹´«Ã½ articles
1
Exclusive report: Inside Chernobyl, 40 years after nuclear disaster
2
Collapse of key ocean current may release billions of tonnes of carbon
3
The biggest threat to Chernobyl is no longer radiation
4
How autoimmune conditions can unexpectedly drive mental illness
5
The man who crawls into the perilous heart of the Chernobyl reactor
6
A key solution to climate change isn't happening – and that's good
7
Electric vehicle owners could earn thousands by supporting power grid
8
My life as a meteorologist in Chernobyl under Russian occupation
9
Neanderthal infants were enormous compared with modern humans
10
Plug-in solar is coming – how dangerous is it and is it worth it?
